, Volume 47, Supplement 2, pp 25–34

Postmenopausal Hormone Replacement Therapy, Coronary Heart Disease and Plasma Lipoproteins

  • Mary Seed

DOI: 10.2165/00003495-199400472-00006

Cite this article as:
Seed, M. Drugs (1994) 47(Suppl 2): 25. doi:10.2165/00003495-199400472-00006


This review outlines the changes in serum lipoprotein (Lp) concentrations at the menopause. The effect of hormone replacement therapy with estrogen and a variety of progestogens is illustrated by a number of recent studies. Analysis of the effects of estrogen replacement in the primary prevention of coronary heart disease (CHD) is discussed. During the last 4 years, there have been 4 observational studies of the use of estrogen in postmenopausal women with CHD as assessed by coronary angiography. In all of these studies, estrogen has been associated with a reduction in CHD, most strikingly in a study of survival over 10 years. However, there is an overwhelming need for a randomised controlled trial of estrogen for secondary prevention. The role of estrogen in the treatment of type II hyperlipoproteinaemia has been recognised, and a study describing its effect is discussed. Again, there is need for data from well controlled clinical trials to clearly establish the benefits of estrogen therapy. A further aspect for investigation is a study of the non-lipoprotein-mediated effects of estrogen, particularly those on vasomotion. Finally, the intriguing effects of both androgenic and estrogenic steroids on Lp(a) are discussed.

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Mary Seed
    • 1
  1. 1.Department of MedicineCharing Cross and Westminster Medical SchoolLondonEngland

Personalised recommendations